Issues on peritoneal metastasis of gastric cancer: an update

Table 1 The clinical application of systematic chemotherapy plus surgery for gastric cancer patients with peritoneal metastasis

Authors reference	Year	Country	Patients	N of PM	Systemic therapy	MST (m)	1-year OS (%)	R0 resection (%)
Ishigami et al. [30]	2008	Japan	Stage IV GC	9	PTX+S1	--	--	88.9
Okabe et al. [31]	2009	Japan	GC patients with PM	41	S-1 plus DDP	43.2	100	57.9%
Einama et al. [32]	2017	Japan	Stage IV GC	3	S1 + DDP/DTX	14.3	100	100
Kanda et al. [33]	2012	USA	GC with PM	19	5-Fu+ oxaliplatin	30.2	94.7	26.3
Han et al. [34]	2013	Korea	M1 GC	8	FOLFOX/DCF	-	-	50
Fukuchi et al. [35]	2018	Japan	Unresectable GC	44	SP et al	-	-	38.6
Satoh et al. [36]	2012	Japan	Stage IV GC	17	S-1 plus DDP	43.5	-	82.4
Sato et al. [37]	2017	Japan	Unresectable metastatic GC	33	DCS	28	97	27.3
Yamaguchi et al. [38]	2018	Japan	Stage IV GC	115	SP et al	-	-	-
Beom et al. [39]	2018	Korea	Stage IV GC	33	Platinum+5-FU	-	-	-
Ramos et al. [40]	2019	Brazil	Unresectable GC	1	XP et al	-	-	-
Kim [41]	2014	Korea	GC patients with PM	43	5-Fu/titanium silicate-1+DDP	37	-	23.3

DDP, cisplatin; DTX, docetaxel; HIPEC, hyperthermic intraperitoneal chemoperfusion; MMC, mitomycin C; PTX, paclitaxel; FOLFOX, 5-FU, oxaliplatin and leucovorin; DCF, docetaxel, cisplatin, and 5-FU; SP, S-1 plus paclitaxel; DCS, docetaxel, cisplatin, and S-1; XP, capecitabine and cisplatin

ISSN: 1477-7819